Randomized, double-blind, placebo-controlled clinical trial of a two-day regimen of dihydroartemisinin-piperaquine for malaria prevention halted for concern over prolonged corrected QT interval

• Main Authors: Jessica Manning, Pattaraporn Vanachayangkul, Chanthap Lon, Michele Spring, Mary So, Darapiseth Sea, Youry Se, Sok Somethy, Sut Thang Phann, Soklyda Chann, Sabaithip Sriwichai, Nillawan Buathong, Worachet Kuntawunginn, Mashamon Mitprasat, Raveewan Siripokasupkul, Paktiya Teja-Isavadharm, Eugene Soh, Ans Timmermans, Charlotte Lanteri, Jaranit Kaewkungwal, Montida Auayporn, Douglas Tang, Char Meng Chour, Satharath Prom, Mark Haigney, Louis Cantilena, David Saunders
• Other Authors: Armed Forces Research Institute of Medical Sciences, Thailand
• Format: Article
• Published: 2018
• Subjects: Medicine; Pharmacology, Toxicology and Pharmaceutics
• Online Access: https://repository.li.mahidol.ac.th/handle/123456789/34184
• Institution: Mahidol University

© 2014 American Society for Microbiology. All Rights Reserved. Dihydroartemisinin-piperaquine, the current first-line drug for uncomplicated malaria caused by Plasmodium falciparum and Plasmodium vivax in Cambodia, was previously shown to be of benefit as malaria chemoprophylaxis when administered a...